Bildkälla: Stockfoto

Alligator Bioscience: Q4 2022, Successful Readout with Mitazalimab - Redeye

Redeye comments on Alligator’s Q4 report. The key event during the quarter was mitazalimab showing strong results (an ORR of 52%) in the interim readout from OPTIMIZE-1, which derisks the clinical development.

Redeye comments on Alligator’s Q4 report. The key event during the quarter was mitazalimab showing strong results (an ORR of 52%) in the interim readout from OPTIMIZE-1, which derisks the clinical development.
Börsvärldens nyhetsbrev
ANNONSER